VALSARTAN ( DrugBank: Valsartan )
7 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 57 | 特発性拡張型心筋症 | 1 |
| 58 | 肥大型心筋症 | 10 |
| 66 | IgA腎症 | 7 |
| 75 | クッシング病 | 1 |
| 218 | アルポート症候群 | 1 |
| 222 | 一次性ネフローゼ症候群 | 5 |
| 224 | 紫斑病性腎炎 | 3 |
57. 特発性拡張型心筋症
臨床試験数 : 11 / 薬物数 : 23 - (DrugBank : 12) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01917149 (ClinicalTrials.gov) | March 2005 | 30/7/2013 | Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy | Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy | Dilated Cardiomyopathy | Drug: Benazepril;Drug: Valsartan;Drug: Metoprolol | Xijing Hospital | NULL | Completed | 18 Years | 70 Years | Both | 480 | Phase 4 | China |
58. 肥大型心筋症
臨床試験数 : 126 / 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-003098-24-GB (EUCTR) | 30/04/2020 | 21/02/2020 | Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy | A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM) | non-obstructive hypertrophic cardiomyopathy MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Entresto Product Name: LCZ696 50 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 100 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 200 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 44 | Phase 2 | United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of | ||
| 2 | EUCTR2019-003098-24-GR (EUCTR) | 16/04/2020 | 13/04/2020 | Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy | A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM) | non-obstructive hypertrophic cardiomyopathy MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Entresto Product Name: LCZ696 50 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 100 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 200 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 44 | Phase 2 | United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of | ||
| 3 | EUCTR2019-003098-24-FI (EUCTR) | 15/04/2020 | 02/03/2020 | Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy | A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM) | non-obstructive hypertrophic cardiomyopathy MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Entresto Product Name: LCZ696 50 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 100 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 200 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN | Novartis Pharma AG | NULL | Not Recruiting | Female: yes Male: yes | 44 | Phase 2 | United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of | ||
| 4 | EUCTR2019-003098-24-ES (EUCTR) | 19/02/2020 | 02/12/2019 | Study of efficacy of oral sacubitril/valsartan adult patients with non-obstructive hypertrophic cardiomyopathy | A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM) | non-obstructive hypertrophic cardiomyopathy MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Entresto Product Name: LCZ696 50 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 100 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 200 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN | Novartis Farmacéutica, S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 44 | Phase 2 | Greece;United States;Finland;Korea, Republic of;United Kingdom;Germany;Spain | ||
| 5 | NCT04164732 (ClinicalTrials.gov) | January 8, 2020 | 13/11/2019 | Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy | A Multi-center, Randomized, Placebo-controlled Patient and Investigator-blinded Study to Explore the Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy (nHCM) | Cardiomyopathy, Hypertrophic | Drug: LCZ696;Drug: Placebo | Novartis Pharmaceuticals | NULL | Active, not recruiting | 18 Years | N/A | All | 45 | Phase 2 | United States;Germany;Greece;Korea, Republic of;Spain;United Kingdom;Finland |
| 6 | EUCTR2019-003098-24-DE (EUCTR) | 18/12/2019 | 05/11/2019 | Study of efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy | A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyopathy (nHCM) | non-obstructive hypertrophic cardiomyopathy MedDRA version: 20.0;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Entresto Product Name: LCZ696 50 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 100 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN Trade Name: Entresto Product Name: LCZ696 200 mg Product Code: LCZ696 INN or Proposed INN: sacubitril/valsartan Other descriptive name: SACUBITRIL VALSARTAN | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 44 | Phase 2 | United States;Greece;Finland;Spain;Germany;United Kingdom;Korea, Republic of | ||
| 7 | NCT03832660 (ClinicalTrials.gov) | May 3, 2019 | 1/2/2019 | Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy | Clinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy | Behavioral: Lifestyle;Drug: Sacubitril/Valsartan | Newcastle University | Azienda Ospedaliero-Universitaria Careggi;University Hospital Regensburg;Institute for Cardiovascular Diseases of Vojvodina;University of Belgrade | Completed | 18 Years | 70 Years | All | 168 | Phase 2 | Germany;Italy;Serbia;United Kingdom |
| 8 | NCT05366101 (ClinicalTrials.gov) | April 1, 2019 | 1/2/2019 | Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy | Clinical and Genetic Determinants of Disease Progression and Response to Lifestyle and Pharmacological Interventions in Patients With Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy | Drug: Sacubitril/Valsartan;Behavioral: Lifestyle | Newcastle-upon-Tyne Hospitals NHS Trust | University Hospital Regensburg;Assistance Publique - Hôpitaux de Paris;Azienda Ospedaliero-Universitaria Careggi;Institute for Cardiovascular Diseases of Vojvodina | Completed | 18 Years | 70 Years | All | 168 | Phase 2/Phase 3 | United Kingdom |
| 9 | EUCTR2015-002283-16-DK (EUCTR) | 08/03/2016 | 16/12/2015 | An international study of the effect of Valsartan in hypertrophic cardiomyopathy. | Phase II randomized, placebo-controlled, double blind clinical trial of valsartan for attenuating disease evolution in early sarcomeric HCM - VANISH | Hypertrophic cardiomyopathy MedDRA version: 19.0;Level: LLT;Classification code 10020204;Term: HOCM Hypertrophic obstructive cardiomyopathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Diovan 40 mg INN or Proposed INN: VALSARTAN Other descriptive name: Diovan Trade Name: Diovan 80 mg INN or Proposed INN: VALSARTAN Other descriptive name: Diovan Trade Name: Diovan 160 mg INN or Proposed INN: VALSARTAN | National Heart, Lung, and Blood Institute / National Institutes of Health | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Denmark | ||
| 10 | NCT01912534 (ClinicalTrials.gov) | March 2014 | 5/6/2013 | Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM | Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM | Hypertrophic Cardiomyopathy | Drug: Valsartan;Drug: Placebo | HealthCore-NERI | National Heart, Lung, and Blood Institute (NHLBI) | Completed | 8 Years | 45 Years | All | 211 | Phase 2 | United States;Canada |
66. IgA腎症
臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR2200006488 | 2022-08-01 | 2022-08-15 | A clinical study of traditional Chinese medicine combined with western medicine in treatment of primary IgA nephropathy (IgAN) in CKD stage 3 | A clinical study of traditional Chinese medicine combined with western medicine in treatment of primary IgA nephropathy (IgAN) in CKD stage 3 | IgA nephropathy | Valsartan:oral valsartan;group combination of Chinese and Western medicine:Valsartan+Chuanhuang No.1 prescription; | Shanghai east hospital (East Hospital affiliated to Tongji University) | NULL | Pending | 18 | 75 | Both | Valsartan:42;group combination of Chinese and Western medicine:21; | China | |
| 2 | ChiCTR-IOR-16010174 | 2016-12-01 | 2016-12-16 | Clinical Study on Treatment of spleen and kidney Yang deficiency type of IgA nephropathy proteinuria with 'Huangqi guizhi wuwu' decoction | Clinical Study on Treatment of spleen and kidney Yang deficiency type of IgA nephropathy proteinuria with 'Huangqi guizhi wuwu' decoction | IgA nephropathy | Basic treatment+Valsartan Capsules treatment group:Basic treatment+Valsartan Capsules treatment ;Basic treatment+Huangqi guizhi wuwu decoction treatment group:Basic treatment+Huangqi guizhi wuwu decoction treatment; | Shuguang Hospital affliliated to Shanghai Univesrity of TCM | NULL | Recruiting | 18 | 65 | Both | Basic treatment+Valsartan Capsules treatment group:50;Basic treatment+Huangqi guizhi wuwu decoction treatment group:50; | China | |
| 3 | NCT02765594 (ClinicalTrials.gov) | June 2016 | 30/4/2016 | Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy | Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study | Primary IgA Nephropathy | Drug: Hydroxychloroquine Sulfate;Drug: Valsartan | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 60 Years | All | 98 | Phase 4 | China |
| 4 | NCT01129557 (ClinicalTrials.gov) | September 2009 | 21/5/2010 | Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease | Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease | Proteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, Membranous | Drug: Aliskiren;Drug: Valsartan | Columbia University | Novartis Pharmaceuticals | Terminated | 18 Years | N/A | All | 46 | Phase 4 | United States |
| 5 | NCT00426348 (ClinicalTrials.gov) | May 2007 | 23/1/2007 | A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy | A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy | Glomerulonephritis;IGA Nephropathy | Drug: Valsartan;Drug: Probucol;Drug: Placebo | Guangdong General Hospital | NULL | Completed | 18 Years | 60 Years | Both | 75 | Phase 4 | China |
| 6 | JPRN-C000000380 | 2003/04/01 | 31/03/2006 | The renoprotective effects of ARB in patients with IgA nephropathy : multicenter,radomized trial | The renoprotective effects of ARB in patients with IgA nephropathy : multicenter,radomized trial - ARB and IgA nephropathy | IgA nephropathy | ARB valsartan ACE-I enalapril | ARB therapeutic society of IgA nephropathy | NULL | Complete: follow-up complete | 16years-old | 75years-old | Male and Female | 400 | Phase 4 | Japan |
| 7 | NCT00367562 (ClinicalTrials.gov) | January 1996 | 22/8/2006 | Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy | Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy | IGA Nephropathy | Drug: ENALAPRIL VALSARTAN METHYLPREDNISONE | Hospital Britanico | NULL | Completed | 21 Years | 70 Years | Both | 20 | Phase 4 | Argentina |
75. クッシング病
臨床試験数 : 205 / 薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000002925 | 2009/12/01 | 28/12/2009 | Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. | Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. - A pilot study to compare efficacy of Eplerenone monotherapy with Valsartan monotherapy. | Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. | 50mg of Eplerenone monotherapy once daily for 6 weeks on subclinical Cushing's syndrome 80mg of Valsartan monotherapy once daily for 6 weeks on subclinical Cushing's syndrome 50mg of Eplerenone monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma 80mg of Valsartan monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma | Hiroshima University HospitalDepartment of Endocrinology and Diabetes mellitus | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 80 | Not selected | Japan |
218. アルポート症候群
臨床試験数 : 30 / 薬物数 : 36 - (DrugBank : 15) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 46
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00309257 (ClinicalTrials.gov) | January 2004 | 30/3/2006 | Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome | Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome | Alport Syndrome | Drug: ACE I, ATA II and Statins;Drug: Benazepril, Valsartan and Fluvastatin | Mario Negri Institute for Pharmacological Research | NULL | Completed | 15 Years | 70 Years | Both | 9 | Phase 2 | Italy |
222. 一次性ネフローゼ症候群
臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100050967 | 2021-09-30 | 2021-09-08 | A controlled clinical trial of the efficacy and safety of sacubitril/valsartan in reducing urinary protein in patients with low-risk membranous nephropathy | A controlled clinical trial of the efficacy and safety of sacubitril/valsartan in reducing urinary protein in patients with low-risk membranous nephropathy | membranous nephropathy | Experimental group:Conventional therapy+sacubitril/valsartan 100mg bid;Control group:Conventional therapy+valsartan 160mg qd; | China-Japan Friendship Hospital | NULL | Recruiting | 30 | 75 | Both | Experimental group:50;Control group:50; | Phase 4 | China |
| 2 | ChiCTR1800020241 | 2019-01-01 | 2018-12-20 | Investigation for Risk Factors of Membrane Nephropathy in Guangxi and Study for Intervention of Vitamin D | Disease diagnosis and treatment technology and standardized research and development and application demonstration | Idiopathic membranous nephropathy | Vitamin D group:Active Vitamin D 0.5ug/day;Valsartan group:Valsartan capsule 160mg/day;Combined treatment group:Active vitamin D 0.5ug / day + valsartan capsule 160mg / day; | The People's Hospital of Guangxi Zhuang Autonomous Region | NULL | Recruiting | 14 | 100 | Both | Vitamin D group:40;Valsartan group:40;Combined treatment group:40; | China | |
| 3 | ChiCTR-INR-17012070 | 2017-09-19 | 2017-07-20 | Yongquan acupoint Shenque moxibustion curative effect of traditional Chinese medicine in the treatment of membranous nephropathy | Yongquan acupoint Shenque moxibustion curative effect of traditional Chinese medicine in the treatment of membranous nephropathy | Membranous nephropathy | Test group :Yongquan Shenque paste of Chinese medicine with mild moxibustion;control group:Valsartan Tablets; | Shijiazhuang Nephropathy Hospital | NULL | Pending | 18 | 75 | Both | Test group :75;control group:75; | China | |
| 4 | NCT01129557 (ClinicalTrials.gov) | September 2009 | 21/5/2010 | Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease | Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease | Proteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, Membranous | Drug: Aliskiren;Drug: Valsartan | Columbia University | Novartis Pharmaceuticals | Terminated | 18 Years | N/A | All | 46 | Phase 4 | United States |
| 5 | NCT00518219 (ClinicalTrials.gov) | July 2007 | 16/8/2007 | To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) | To Compare the Efficacy and Safety of TW vs Valsartan in the MN | Membranous Nephropathy | Drug: TW | Nanjing University School of Medicine | NULL | Completed | 18 Years | 65 Years | Both | 68 | Phase 4 | China |
224. 紫斑病性腎炎
臨床試験数 : 16 / 薬物数 : 43 - (DrugBank : 21) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 58
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR2100004424 | 2020-11-06 | 2020-11-06 | A single center randomized controlled clinical study on the treatment of Children with Purpura nephritis with Huai-Qi-Huang Granules | A single center randomized controlled clinical study on the treatment of Children with Purpura nephritis with Huai-Qi-Huang Granules | Children with purpura nephritis | experimental group:Huaiqihuang;control group:valsartan; | Children's Hospital, Zhejiang University School of Medicine | NULL | Recruiting | 6 | 14 | Male | experimental group:5;control group:5; | China | |
| 2 | ChiCTR2000039700 | 2020-11-06 | 2020-11-06 | A single center randomized controlled clinical study on the treatment of Children with Purpura nephritis with Huai-Qi-Huang Granules | A single center randomized controlled clinical study on the treatment of Children with Purpura nephritis with Huai-Qi-Huang Granules | Children with purpura nephritis | experimental group:Huaiqihuang;control group:valsartan; | Children's Hospital, Zhejiang University School of Medicine | NULL | Recruiting | 6 | 14 | Male | experimental group:5;control group:5; | China | |
| 3 | NCT04623866 (ClinicalTrials.gov) | November 1, 2020 | 25/10/2020 | Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules | A Single Center Randomized Controlled Clinical Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules | Henoch Schönlein Purpura Nephritis | Drug: Huaiqinhuang;Drug: valsartan | The Children's Hospital of Zhejiang University School of Medicine | NULL | Not yet recruiting | 6 Years | 14 Years | All | 10 | Early Phase 1 | China |